Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-12-15
2010-10-12
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388850, C424S130100, C424S133100, C424S141100, C424S152100, C536S023530, C435S320100, C435S091400, C435S069600
Reexamination Certificate
active
07812133
ABSTRACT:
The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.
REFERENCES:
patent: 5457035 (1995-10-01), Baum et al.
patent: 6333035 (2001-12-01), Sugamura et al.
patent: 6528623 (2003-03-01), Godfrey et al.
patent: 7291331 (2007-11-01), Croft et al.
patent: 7501496 (2009-03-01), Endl et al.
patent: 2004/0009174 (2004-01-01), Arndt et al.
patent: 2005/0034179 (2005-02-01), Sugamura et al.
patent: 2005/0042718 (2005-02-01), Bazin et al.
patent: 2005/0069548 (2005-03-01), Hussell et al.
patent: 2006/0002929 (2006-01-01), Khare et al.
patent: 2006/0069548 (2006-03-01), Matsuura
patent: 95/12673 (1995-05-01), None
patent: 95/21915 (1995-08-01), None
patent: 99/15200 (1999-04-01), None
patent: 03/059245 (2003-07-01), None
patent: 03/082919 (2003-10-01), None
patent: 2004/019866 (2004-03-01), None
patent: 2006/029879 (2006-03-01), None
patent: 2008/106116 (2008-09-01), None
Rudikoff, Giusti, Cook, and Sharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Granziero, Krajewski, Farness, Yuan, Courtney, Jackson, Peterson, and Vitiello. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. European Journal of Immunology, 1999. vol. 29, pp. 1127-1138.
Byers. What can randomized controlled trials tell us about nutrition and cancer prevention? CA Cancer Journal, 1999. vol. 49, pp. 353-361.
Akiba, et al., “CD28-Independent Costimulation of T Cells by OX40 Ligand and CD70 on Activated B Cells”The Journal of Immunologypp. 7058-7066 (1999).
Miura et al., “Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax”Molecular&Cellular Biology11(3) :1313-1325 (1991).
Nohara, C., et al., “Amelioration of Experimental Autoimmune Encephalomyelitis with Anti-OX40 Ligand Monoclonal Antibody: A Critical Role for OX40 Ligand in Migration, but not Development, of Pathogenic T Cells”Journal of Immunology41:2108-2115 (2001).
Satake, Y., et al., “Characterization of Rat OX40 Ligand by Monoclonal Antibody”Biochemical and Biophysical Research Communications270:1041-1048 (2000).
Totsuka, et al., “Therapeutic Effect of Anti-OX40L and Anti-TNF-α MAbs in a Murine Model of Chronic Colitis”Am. J. Physio. Gastrointest Liver Physiol284:G595-G603 (2003).
Tozawa et al., “Species-dependent antigenicity of the 34-kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human T-cell leukemia virus type-I (HTLV-I) and simian T-cell leukemia virus (STLV-I)”Int. J. Cancer41:231-238 (1988).
Baum et al., “Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34”EMBO Journal13 (17) :3992-4001 (1994).
Burgess et al., “Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma?”J Allergy Clin Immunol. 113 (4) :683-9 (Apr. 2004).
Godfrey, W. et al., “Stan-40, a new member of the FAS-TNFr superfamily expressed selectively on activated, human CD4+ T cells”J. Cellular Biochemistry(V370)Suppl. 18D:355 (1994).
Higgins et al., “Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein”J Immunol. 162 (1):486-93 (Jan. 1999).
Humphreys et al., “A critical role for OX40 in T cell-mediated immunopathology during lung viral infection”J Exp Med. 198(8):1237-42 (Oct. 2003).
Imura et al., “OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration”Blood89 (8) :2951-8 (Apr. 1997).
Imura et al., “The Human OX40/gp34 System Directly Mediates Adhesion of Activated T Cells to Vascular Endothelial Cells”Journal of Experimental Medicine183 (5) :2185-2195 (May 1996).
Kjaergaard et al., “Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor”J Immunol. 167 (11) :6669-77 (Dec. 2001).
Lane, “Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells”J Exp Med. 191 (2) :201-6 (Jan. 2000).
Mallett and Barclay, “A new superfamily of cell surface proteins related to the nerve growth factor receptor”Immunol Today12 (7) :220-3 (Jul. 1991).
Mallett et al., “Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes—A Molecule Related to Nerve Growth Factor Receptor”EMBO Journal9 (4) :1063-1068 (Apr. 1990).
Ndhlovu et al., “Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis”J Immunol. 167 (5) :2991-9 (Sep. 2001).
Ohshima et al., “Expression and function of OX40 ligand on human dendritic cells”J Immunol. 159 (8) :3838-48 (Oct. 1997).
Rogers et al., “OX40 promotes Bcl-xL and Bcl-2 expression and is essential for ling-term survival of CD4 T cells”Immunity15(3):445-55 (Sep. 2001).
Stuber and Strober, “The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response”J Exp Med. 183 (3) :979-89 (Mar. 1996).
Stuber et al., “Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease”Gastroenterology115(5):1205-15 (Nov. 1998).
Sugamura et al., “Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40”Nat Rev Immunol. 4 (6) :420-31 (Jun. 2004).
Takahashi et al., “OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection”J Virol. 75 (15) :6748-57 (Aug. 2001).
Takasawa et al., “Expression of gp34 (OX40 ligand) and OX40 on human T cell clones”Jpn J Cancer Res. 92 (4) :377-82 (Apr. 2001).
Takeda, “Distinct roles for the
Coburn Cara
Genentech, Inc
Gussow Anne M.
LandOfFree
Anti-OX40L antibodies and methods using same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-OX40L antibodies and methods using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-OX40L antibodies and methods using same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175544